Scarica l'app Stockscreener
121.17
0.89%
-1.09
Inhibrx Biosciences Inc Borsa (INBX) Ultime notizie
Stifel reiterates Buy on Inhibrx Biosciences stock, $325 target By Investing.com - Investing.com Canada
Inhibrx (INBX) Results at a Glance: The Bottom-Line Figure Trails Its Comparison in the Available Record; Trading Response: The Market Price Declines 2.92% in the Available RecordNegative Surprise Momentum - vinanet.vn
Western Standard LLC Takes $4.45 Million Position in Inhibrx Biosciences, Inc. $INBX - MarketBeat
Inhibrx (INBX) Q1 2026 Results: EPS Falls Short of Its Estimate in the Current Update; Market Move: The Stock Gains 7.25% at the CloseEarnings Stability Report - vinanet.vn
Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $325 - Moomoo
Inhibrx Biosciences (NASDAQ:INBX) Downgraded to Strong Sell Rating by Wall Street Zen - MarketBeat
INBX Q1 2026 Earnings: Wider-than-Expected Loss Reflects Elevated Pipeline InvestmentReturn On Capital - vinanet.vn
Should FDA Review of Ozekibart and INBRX-106 Data Milestones Require Action From Inhibrx (INBX) Investors? - simplywall.st
Trading the Move, Not the Narrative: (INBX) Edition - Stock Traders Daily
Inhibrx Biosciences expands clinical evaluation of Ozekibart in new cancer study cohorts - Traders Union
Inhibrx Biosciences (INBX) Falls 8.9% to $88.37 as Downside Pressure BuildsUp Down Ratio - Vinanet
Inhibrx Biosciences (INBX) holders disclose 1.49M-share, 9.99% position - Stock Titan
Schonfeld Strategic Advisors (INBX) discloses 5.33% Inhibrx Biosciences stake in 13G filing - Stock Titan
Inhibrx (INBX): Viking Global group discloses 9.3% beneficial ownership stake - Stock Titan
Inhibrx Biosciences (INBX) Slides 8% to $89.22: Support at $84.76 Becomes Key TestNHNL Divergence - vinanet.vn
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $230 - Moomoo
Buy Rating Reaffirmed on Inhibrx Ahead of Key INBRX-106 Phase 2 Readout; $230 Price Target Maintained - TipRanks
Inhibrx Biosciences (NASDAQ:INBX) Shares Gap Down After Earnings Miss - MarketBeat
Inhibrx Biosciences, Inc. (NASDAQ:INBX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
INBX SWOT Analysis: Financial Challenges and Promising Pipeline Revealed in 10-Q Filing - GuruFocus
Inhibrx Biosciences (NASDAQ:INBX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS - MarketBeat
Form 8K Inhibrx Biosciences Inc For: 13 August By Investing.com - Investing.com Nigeria
Inhibrx Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Inhibrx Biosciences (INBX) deepens losses but reports pivotal ozekibart and INBRX-106 data - Stock Titan
Inhibrx Reports Second Quarter 2026 Financial Results - PR Newswire
FDA Sets April 2027 Goal Date for Inhibrx's Ozekibart - Stock Titan
Inhibrx Biosciences (INBX) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Wall Street Zen Upgrades Inhibrx Biosciences (NASDAQ:INBX) to "Hold" - MarketBeat
Inhibrx Biosciences (INBX) to Announce Quarterly Earnings on Wednesday - MarketBeat
(INBX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Inhibrx Biosciences (INBX) sees 5.9% ownership reported by Bank of America - Stock Titan
Swiss National Bank Invests $968,000 in Inhibrx Biosciences, Inc. $INBX - MarketBeat
Inhibrx Biosciences (NASDAQ:INBX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Ongoing studies in rare cancer gain traction for Inhibrx Biosciences amid urgent patient needs - Traders Union
Healthcare of Ontario Pension Plan Trust Fund Sells 93,300 Shares of Inhibrx Biosciences, Inc. $INBX - MarketBeat
INBX|Inhibrx Biosciences Inc|Price:82.350|Chg%:+0.800 - TradingKey
Inhibrx Biosciences urges expanded research to address unmet needs in head and neck cancer - Traders Union
Inhibrx Biosciences, Inc. $INBX Shares Bought by SummitTX Capital L.P. - MarketBeat
TradingKey - TradingKey
Inhibrx Biosciences Inc (INBX) Balance Sheet - TradingKey
Inhibrx Biosciences, Inc. Revenue Breakdown – NASDAQ:INBX - TradingView
Inhibrx Biosciences Inc (INBX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Inhibrx Biosciences Inc (INBX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Inhibrx Biosciences (INBX) Declines 4% as Stock Pulls Back From Resistance ZoneChaikin Flow - Vinanet
Inhibrx Biosciences: The Whole Story Rides On INBRX-106 (NASDAQ:INBX) - Seeking Alpha
INBX|Inhibrx Biosciences Inc|Price:81.550|Chg%:-3.450 - TradingKey
Inhibrx Biosciences Inc (INBX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price-Driven Insight from (INBX) for Rule-Based Strategy - Stock Traders Daily
INBX Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Reports Operating LossesBuyback Announcement Report - Vinanet
INBX Q1 2026 Earnings: Wider-than-Expected Loss Weighs on SharesReturn On Assets - Vinanet
Inhibrx Biosciences (INBX) Faces Headwinds as Stock Dips 1.89% – Support Test AheadChandelier Stop - dars.gov.et
Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act (NASDAQ:INBX) - Seeking Alpha
Inhibrx Biosciences Expands Credit Facility to $500 Million - TipRanks
Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 million - Bitget
Inhibrx Biosciences Secures $500 Million Credit Facility with Oxford Finance to Accelerate Clinical Pipeline Expansion - Minichart
Inhibrx expands credit facility to $500 million with Oxford By Investing.com - Investing.com South Africa
Inhibrx Biosciences Expands Oxford Credit Facility to $500 Million, Draws $100 Million, Issues Warrants - TradingView
Inhibrx Biosciences (Nasdaq: INBX) secures up to $500M Oxford credit - Stock Titan
Inhibrx Shares Fall After Expanding Loan Agreement to $500M - Moomoo
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):